Vera Therapeutics (VERA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Vera Therapeutics

NasdaqGM•Healthcare•Biotechnology

$34.27+2.50(0.08%)After hours

Market Cap

$2.46B

P/B

6.0x

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

How this company scores

WeakMetricSide Score: 30/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (3/25).

Profitability3/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Low leverageImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 6.0x5y range 1.8x – 8.4x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $2.46B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-415.22M
TTM Op. Income: $-415.76M
Q. Op. Income: $-112.49M
TTM Net Income: $-401.89M
Q. Net Income: $-109.47M
EPS: $-1.52
Shares Out.: $71.84M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-415.22M and TTM operating income of $-415.76M show growth is flowing through to the bottom line. However, net income is negative at $401.89M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -11249000000.0%
Net Margin: -10947300000.0%

Op. margin of -11249000000.0% is down 3234900000.0% YoY — costs are rising relative to revenue. Net margin at -10947300000.0% Over the past year, operating margin is down 40% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 6.0x

P/S of 0.0x and P/B of 6.0x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $532.98M
Cash: $48.88M
Long-Term Debt: $75.23M
Book Value: $407.76M
D/E Ratio: 0.2
Debt/EBITDA: N/A

With $532.98M in assets and $75.23M in long-term debt, D/E is 0.2and book value is $407.76M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 2 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-100.25M
TTM Free Cash Flow: $-338.91M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-338.91M on $-100.25M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 7 consecutive quarters — a weakening trend.